2011
Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity
Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity. Molecular Cancer Therapeutics 2011, 10: 1300-1307. PMID: 21571911, DOI: 10.1158/1535-7163.mct-11-0259.Peer-Reviewed Original ResearchConceptsHepatic arterial infusionNab-paclitaxelHepatic extractionArterial infusionDose levelsNanoparticle Albumin-Bound PaclitaxelFirst-pass hepatic extractionPredominant liver metastasesCommon adverse eventsAdvanced cancer patientsAlbumin-Bound PaclitaxelDose-limiting toxicityPeak concentrationHighest dose levelStable diseaseAdverse eventsLiver involvementLiver metastasesPartial responseI trialComparative pharmacokinetic studyHepatic metastasesPoor outcomeCancer patientsNanoparticle albumin
2008
Is embolization of segment 4 portal veins before extended right hepatectomy justified?
Kishi Y, Madoff DC, Abdalla EK, Palavecino M, Ribero D, Chun YS, Vauthey JN. Is embolization of segment 4 portal veins before extended right hepatectomy justified? Surgery 2008, 144: 744-751. PMID: 19081016, PMCID: PMC5901738, DOI: 10.1016/j.surg.2008.05.015.Peer-Reviewed Original ResearchConceptsPreoperative portal vein embolizationPortal vein embolizationPortal veinHypertrophy rateVein embolizationRight portal vein embolizationExtended right hepatectomyLiver remnant volumeMajor hepatectomyRight hepatectomyCurative hepatectomySubsequent resectionClinical outcomesRemnant volumeEmbolizationComplicationsPatientsAbsolute increaseHepatectomyUninjured liverSignificant differencesVeinSegment 2Volume gainResection